Present Status of Gelatin Sponge for the Control of Hemorrhage

Jenkins, Hilger Perry

doi:10.1001/jama.1946.02870460004002

Cited by 50 publications

(20 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The high rupture rates of pseudoaneurysms necessitate immediate treatment. [3] The treatment of choice is the selective endovascular embolization of the feeding artery proximal to the hepatic pseudoaneurysm [9]. Embolizing agents such as coils, Gelfoam, arterial stents, and detachable silicone balloons have been used successfully in the course of such treatment [9,10].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prophylactic embolization of hepatic artery pseudoaneurysm after blunt abdominal trauma in a child

Miao

Wong

et al. 2010

Journal of Pediatric Surgery

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…In selective angiography (nontarget embolizations), there is the risk of collateral damage to surrounding healthy liver, catheter-related vascular injuries, and tissue necrosis in the liver, although the latter is less of a concern because of the liver's dual blood supply [9].…”

Section: Discussionmentioning

confidence: 99%

Prophylactic embolization of hepatic artery pseudoaneurysm after blunt abdominal trauma in a child

Miao

Wong

et al. 2010

Journal of Pediatric Surgery

View full text Add to dashboard Cite

“…Although its mode of action has not been fully explained yet, it is believed that the sponge-like physical characteristics of the gelatine sponge stimulate the formation of blood clots [10]. As long as Gelfoam is not applied in excessive amounts, it is fully resorbed within a period of approximately four to six weeks.…”

Section: Gelfoammentioning

confidence: 99%

Transcatheter arterial embolisation in upper gastrointestinal bleeding in a sample of 29 patients in a gastrointestinal referral center in Germany

et al. 2015

View full text Add to dashboard Cite

Objective: This is a retrospective analysis of interventional embolisation performed with catheter angiography in 29 patients with upper gastrointestinal bleeding in the setting of a secondary care hospital. Patients, Materials, and Methods: From April 2007 to February 2013, 29 patients with upper gastrointestinal bleeding underwent endovascular diagnostics and treatment. The diagnosis was established by endoscopy, computed tomography or clinically based on a significant decrease in hemoglobin. Transcatheter arterial embolisation was performed with coils, liquid embolic agents, and particles. The technical and clinical outcomes were assessed by postinterventional endoscopy, hemoglobin concentrations, number of necessary transfusions, or surgical interventions, as well as by post-interventional mortality within 28 days after the procedure. Results: Selective angiographic embolisation in upper gastrointestinal bleeding was primarily successful technically and clinically in 22 of 29 patients. In 4/29 cases an angiographic reintervention was performed, which was successful in 3?cases. In 3 cases of primarily technically unsuccessful procedures reintervention was not attempted. No catheterisation-related complications were recorded. Peri-interventional mortality was 31?%, but only 2 of these patients died due to uncontrolled massive bleeding, whereas the lethal outcome in the other 7 patients was due to their underlying diseases. Conclusion: Transcatheter arterial embolisation is an effective and rapid method in the management of upper gastrointestinal bleeding. Radiological endovascular interventions may considerably contribute to reduced mortality in GI bleeding by avoiding a potential surgical procedure following unsuccessful endoscopic treatment. The study underlines the importance of the combination of interventional endoscopy with interventional radiology in secondary care hospitals for patient outcome in complex and complicated upper gastrointestinal bleeding situations.

show abstract

“…Surface-acting devices, when applied directly to bleeding surfaces, arrest bleeding by the formation of an artificial clot and by producing a mechanical matrix that facilitates clotting (28). Jenkins et al have theorized that the clotting effect of Gelfoam may be due to release of thromboplastin from platelets, occurring when platelets entering the Gelfoam become damaged by contact with its myriad of interstices (29). Thromboplastin interacts with prothrombin and calcium to produce thrombin, and this sequence of events initiates the clotting reaction.…”

Section: Background-immunotherapy In Prostate Cancermentioning

confidence: 99%

“…Thromboplastin interacts with prothrombin and calcium to produce thrombin, and this sequence of events initiates the clotting reaction. The authors suggest that the physiologic formation of thrombin in Gelfoam is sufficient to produce formation of a clot, by its action on the fibrinogen in blood (29). The spongy physical properties of Gelfoam hasten clot formation and provide structural support for the forming clot (28,30).…”

Section: Background-immunotherapy In Prostate Cancermentioning

confidence: 99%

Vaccine Immunotherapy for Prostate Cancer. Addendum

Lubaroff¹

2007

View full text Add to dashboard Cite

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. Lubaroff, final addendum report REPORT DATE 01-07-2007 REPORT TYPE Final Addendum DATES COVERED Appendices…………………………………………………………………………… 4Lubaroff; final addendum report, page 1. Vaccine Immunotherapy for Prostate Cancer David M. Lubaroff, PhD Principal Investigator Grant Number PC050647 Final Addendum ReportINTRODUCTION: The goal of this Clinical Trial Developmental Award (CTDA) was to develop and complete the required administrative tasks necessary to begin a Phase II clinical trial of an adenovirus/PSA (Ad/PSA) vaccine in men with recurrent prostate cancer and a Phase I clinical trial of the combination of the Ad/PSA vaccine along with immunostimulatory CpG ODN. The tasks included the design and construction of the clinical protocols, informed consent forms, submission to the institutional committees that include the Protocol Review and Monitoring Committee, Human Subjects Committee (IRB), Biosafety Committee, Pharmacy and Therapeutics Committee; the NIH Recombinant DNA Advisory Committee (RAC), and the food and Drug Administration (FDA). In addition, although not funded by the CTDA, we were required by the FDA to perform Pharmacology/Toxicology and Histopathology Studies and to obtain a complete DNA sequence of the Ad/PSA vaccine.BODY: We describe below the accomplishments during the one year extension of the award, using the original Statement of Work tasks. The accomplishments include those previously reported at the end of the original one year award.Sequence the Ad5-PSA vaccine -The clinical grade Ad/PSA vaccine was submitted to Lark Technologies. The sequence report indicated that there were no additions to the normal sequences of the PSA insert nor to the adenovirus backbone.Develop protocols, investigator brochures, and IRB forms for the Phase II trial of the Ad/PSA vaccine alone -This task consumed the great majority of time during the first year of the award. Multiple meetings were held among the Principal Investigator (PI) and members of the Clinical Trial Team to make important decisions about the trial protocols. The discussion point included the patient populations to be targeted in the trials, the...

show abstract

Present Status of Gelatin Sponge for the Control of Hemorrhage

Cited by 50 publications

References 16 publications

Prophylactic embolization of hepatic artery pseudoaneurysm after blunt abdominal trauma in a child

Prophylactic embolization of hepatic artery pseudoaneurysm after blunt abdominal trauma in a child

Transcatheter arterial embolisation in upper gastrointestinal bleeding in a sample of 29 patients in a gastrointestinal referral center in Germany

Vaccine Immunotherapy for Prostate Cancer. Addendum

Contact Info

Product

Resources

About